JPWO2023009841A5 - - Google Patents

Info

Publication number
JPWO2023009841A5
JPWO2023009841A5 JP2024505541A JP2024505541A JPWO2023009841A5 JP WO2023009841 A5 JPWO2023009841 A5 JP WO2023009841A5 JP 2024505541 A JP2024505541 A JP 2024505541A JP 2024505541 A JP2024505541 A JP 2024505541A JP WO2023009841 A5 JPWO2023009841 A5 JP WO2023009841A5
Authority
JP
Japan
Prior art keywords
dosage form
htp
optionally
modified release
release layer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024505541A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024528125A (ja
JP2024528125A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/038914 external-priority patent/WO2023009841A1/en
Publication of JP2024528125A publication Critical patent/JP2024528125A/ja
Publication of JPWO2023009841A5 publication Critical patent/JPWO2023009841A5/ja
Publication of JP2024528125A5 publication Critical patent/JP2024528125A5/ja
Pending legal-status Critical Current

Links

JP2024505541A 2021-07-30 2022-07-29 ５－ヒドロキシトリプトファン胃内滞留性剤形 Pending JP2024528125A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163227915P 2021-07-30 2021-07-30
US63/227,915 2021-07-30
PCT/US2022/038914 WO2023009841A1 (en) 2021-07-30 2022-07-29 5-hydroxytryptophan gastroretentive dosage forms

Publications (3)

Publication Number Publication Date
JP2024528125A JP2024528125A (ja) 2024-07-26
JPWO2023009841A5 true JPWO2023009841A5 (https=) 2025-08-05
JP2024528125A5 JP2024528125A5 (https=) 2025-08-05

Family

ID=83049744

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024505541A Pending JP2024528125A (ja) 2021-07-30 2022-07-29 ５－ヒドロキシトリプトファン胃内滞留性剤形

Country Status (14)

Country Link
US (2) US11752107B2 (https=)
EP (1) EP4362919A1 (https=)
JP (1) JP2024528125A (https=)
KR (1) KR20240039030A (https=)
CN (1) CN116801868A (https=)
AU (1) AU2022320730A1 (https=)
BR (1) BR112024001927A2 (https=)
CA (1) CA3226223A1 (https=)
CL (1) CL2024000271A1 (https=)
CO (1) CO2024002256A2 (https=)
IL (1) IL310523A (https=)
MX (1) MX2024001390A (https=)
WO (1) WO2023009841A1 (https=)
ZA (1) ZA202401725B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12409163B2 (en) 2021-07-30 2025-09-09 Evecxia Therapeutics, Inc. Method of enhancing 5-hydroxytryptophan (5-HTP) exposure
US11779567B2 (en) 2021-10-14 2023-10-10 Evecxia Therapeutics, Inc. Method for optimizing 5-hydroxytryptamine function in the brain for therapeutic purposes
WO2024148354A1 (en) * 2023-01-06 2024-07-11 Evecxia Therapeutics, Inc. A method of enhancing 5-hydroxytryptophan (5-htp) exposure
WO2025042927A2 (en) * 2023-08-24 2025-02-27 Merck Sharp & Dohme Llc Sustained-release formulations for poorly permeable cyclic peptides

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4140755A (en) 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
US4191184A (en) 1977-01-06 1980-03-04 Carlisle Jeffrey A Intravenous infusion regulation system with reciprocal metering means
US4658038A (en) 1982-10-07 1987-04-14 Research Foundation For Mental Hygiene, Inc. N-acylated 5-hydroxytryptophan amide derivatives
IL87710A (en) 1987-09-18 1992-06-21 Ciba Geigy Ag Covered floating retard form for controlled release in gastric juice
FR2654931B1 (fr) * 1989-11-24 1993-08-27 Trouillas Paul Compositions pharmaceutiques possedant une activite sur l'ataxie et les troubles de l'equilibre, cerebelleux ou autres, de toutes origines, comprenant l'association de l-5-hydroxytryptophane et de carbidopa.
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
CA2290624C (en) 1997-06-06 2006-12-05 John W. Shell Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
IN186245B (https=) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
EP1063973B1 (en) 1998-03-19 2016-11-16 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US7674480B2 (en) 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20060013875A1 (en) 2002-05-29 2006-01-19 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US7094427B2 (en) 2002-05-29 2006-08-22 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
BR0314804A (pt) * 2002-09-28 2005-08-02 Mcneil Ppc Inc Forma de dosagem de liberação modificada
EP1542662A1 (en) 2002-09-28 2005-06-22 McNEIL-PPC, INC. Immediate release dosage form comprising shell having openings therein
AU2003293423A1 (en) 2002-12-06 2004-06-30 Xenoport, Inc. Carbidopa prodrugs and uses thereof
ITMI20041689A1 (it) 2004-09-01 2004-12-02 Bojidar Mihaylov Stankov Nuove formulazioni di rilascio controllato contenenti 5-idrossitriptofano e triptofano
US20080268045A1 (en) 2006-11-09 2008-10-30 Proprius Pharmaceuticals, Inc. Sustained release methotrexate formulations and methods of use thereof
KR20080076382A (ko) 2007-02-15 2008-08-20 (주)아모레퍼시픽 실로스타졸의 제어방출 제제 및 그 제조방법
EP1980743B1 (en) 2007-04-10 2015-09-09 Nissan Motor Co., Ltd. Fuel pump driving device
US8969400B2 (en) 2007-10-01 2015-03-03 Duke University Pharmaceutical compositions of 5-hydroxytryptophan and serotonin-enhancing compound
KR101601649B1 (ko) 2008-04-18 2016-03-09 인텍 파마 리미티드 카르비도파／레보도파 위체류 약물 전달
ZA200903854B (en) 2008-06-19 2011-02-23 Univ Of The Witwatesrand Johannesburg A gastroretentive pharmaceutical dosage form
JP2012500221A (ja) 2008-08-15 2012-01-05 ディポメド，インコーポレイティド Ｃｎｓ障害の処理及び予防のための胃保持性医薬組成物
WO2011146611A1 (en) 2010-05-18 2011-11-24 Abon Pharmaceuticals, Llc Modified gastroretentive drug delivery system for amine drugs
US20130078290A1 (en) * 2010-06-01 2013-03-28 Rubicon Research Private Limited Gastroretentive Dosage Forms Of GABA Analogs
EP2629615B1 (en) 2010-10-22 2018-10-10 Duke University Slow-release formulations of 5-hydroxytryptophan as an adjunct to pro-serotonergic therapies
CN103554005A (zh) 2013-11-22 2014-02-05 长沙理工大学 一种左旋5-羟基色氨酸的简便合成新方法
US20170266112A1 (en) 2014-06-11 2017-09-21 Massachusetts Institute Of Technology Residence structures and related methods
HK1258050A1 (zh) 2015-10-23 2019-11-01 Lyndra Therapeutics, Inc. 用於治疗剂缓释的胃驻留系统及其使用方法
BR112020015068A2 (pt) 2018-01-29 2021-01-05 Duke University Composições e métodos de melhoramento de biodisponibilidade de 5-hidroxitriptofano
CN112469400A (zh) * 2018-06-19 2021-03-09 新加坡国立大学 对于各种适应症的生物利用度更佳的5-羟色氨酸(5-htp)制剂
EP3820468A4 (en) * 2018-07-11 2022-03-23 Duke University Use of sustained-release 5-hydroxytryptophan in treating gastrointestinal disorders

Similar Documents

Publication Publication Date Title
US6703044B1 (en) Venlafaxine formulations
JP2004534031A (ja) 心臓および循環器疾患の治療および予防を目的とする一日一回の治療のための経口制御放出医薬組成物
JPH072635B2 (ja) 新規医薬製剤およびその製造方法
CZ2001901A3 (cs) Farmaceutická kompozice představující systém řízeného dodávání léku pro orální podání, poskytující časovou a místní kontrolu
US20120107400A1 (en) Sustained release composition of theraputic agent
CN105431144A (zh) 阿坎酸制剂、使用阿坎酸制剂的方法以及包含阿坎酸制剂的组合
PT85049B (pt) Processo para a preparacao de uma combinacao de libertacao controlada, de carbidopa/ levodopa
US20180071221A1 (en) Immediate release soluble ibuprofen compositions
US7303761B2 (en) Stabilised pharmaceutical composition comprising an extended release non-steroidal anti-inflammatory agent and an immediate release prostaglandin
CN113476421B (zh) 一种非布司他的控释组合物及其制备方法
ES3021732T3 (en) Soluble rear layer for otf
WO2025201296A1 (zh) 一种含有米诺地尔的药物组合物、制备方法及其应用
US6150410A (en) pH independent extended release pharmaceutical formulation
US8105627B2 (en) Extended release venlafaxine tablet formulation
KR20120075029A (ko) 위체류 약물 전달시스템을 이용한 경구용 방출제어형 레바미피드-함유 이층정 제제 및 그 제조방법
JPWO2023009841A5 (https=)
EP2386302A1 (en) A controlled release pharmaceutical dosage form of trimetazidine and processes for the preparation thereof
CN101022808A (zh) 含有活性组分的胃滞留片剂的药物组合物
US20250312324A1 (en) Prolonged-release oral solid formulation of pirfenidone
CN114404379B (zh) 一种瑞巴派特缓释片及其制备方法
JP2007510654A (ja) 分極した酸素原子を有するポリマーを含むマトリクスからの正に荷電した薬理学的活性分子の徐放
CA2433915A1 (en) Improved controlled release oral dosage form
Honkanen Biopharmaceutical evaluation of orally and rectally administered hard hydroxypropyl methylcellulose capsules
CN101068532B (zh) 布洛芬改进释放剂型
WO2009007762A1 (en) Metronidazole containing extended release floating pharmaceutical composition